Elekta (OTCMKTS:EKTAY) Sees Strong Trading Volume - Still a Buy?

Key Points

• Trading spike: Volume jumped to 10,054 shares—a 282% increase from the prior session—as the stock rose to $5.985 (up about 0.4%).
• Mixed financials: Market cap ~$2.21B with last quarter EPS $0.09 on $433.3M revenue and analysts forecasting FY EPS of 0.36, but the company shows a negative P/E (~-597.9) and a slight negative net margin (-0.08%).
• Business focus: Elekta is a global medical‑technology company specializing in precision radiation therapy and radiosurgery (including linear accelerators, Gamma Knife and brachytherapy) for oncology and neurosurgery.

Elekta AB (OTCMKTS:EKTAY - Get Free Report) saw an uptick in trading volume on Tuesday . 10,054 shares changed hands during mid-day trading, an increase of 282% from the previous session's volume of 2,634 shares.The stock last traded at $5.9850 and had previously closed at $5.87.

Elekta Stock Up 0.4%

The stock's 50 day simple moving average is $6.28 and its two-hundred day simple moving average is $5.69. The firm has a market cap of $2.21 billion, a P/E ratio of -597.90 and a beta of 1.07. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.04 and a quick ratio of 0.79.

Elekta (OTCMKTS:EKTAY - Get Free Report) last issued its quarterly earnings results on Thursday, March 5th. The company reported $0.09 EPS for the quarter. The firm had revenue of $433.29 million for the quarter. Elekta had a positive return on equity of 12.72% and a negative net margin of 0.08%. As a group, research analysts forecast that Elekta AB will post 0.36 earnings per share for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta's offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company's core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.